NOVARTIS AG business relationships

“Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.” SEC filing

“Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and GvHD outside the US.” SEC filing

“Promacta / Revolade is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.” SEC filing

“Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline (GSK).” SEC filing

“Promacta / Revolade is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.” SEC filing

“Lucentis is licensed from Genentech, and Novartis holds the rights to commercialize the product outside the US.” SEC filing

“Novartis co-promotes Xolair with Genentech in the US and shares a portion of operating income, but Novartis does not record any US sales.” SEC filing

“...ollaborators, if any, including milestone, royalty and research and development funding payments from Roche with respect to the development and commercialization of zilebesiran, as well as royalty payments from Novartis and Sanofi related to the commercialization of Leqvio and Qfitlia, respectively;” SEC filing

“• revenue recognized under our license agreement with Novartis associated with the achievement of a specified Leqvio commercialization milestone during the year ended December 31, 2024.” SEC filing

“In January 2026, our collaborator, Novartis, received notice of a Paragraph IV certification for Leqvio.” SEC filing

“...ch as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceu...” SEC filing

“We also have certain rights to intellectual property licensed to Novartis' affiliate under a materials transfer agreement with a third party.” SEC filing

“License Agreement with Novartis International Pharmaceutical Ltd.” SEC filing

“We plan to expand this pipeline over time, both internally and through our target discovery collaboration with Novartis.” SEC filing

“We receive royalties from J&J, Novartis, Roche and Partner Therapeutics based on net” SEC filing

“worldwide by Novartis under a license agreement between Genmab and Novartis.” SEC filing

“pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining” SEC filing

“These include OLUMIANT (baricitinib), which is licensed to our collaborative partner Eli Lilly and Company ("Lilly"), and JAKAVI (ruxolitinib) and TABRECTA (capmatinib), which are licensed to Novartis.” SEC filing

“Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).” SEC filing

“Our collaborators Novartis and Lilly are affected by similar considerations for the drugs that they market and for which we may receive royalties.” SEC filing

“Royalty revenues on commercial sales for JAKAVI and TABRECTA by Novartis are estimated based on information provided by Novartis.” SEC filing

“There are numerous factors, most of which are not within our control, that could materially impact the amount and timing of royalty payments from Biogen and Novartis, and result in changes to our estimate of future royalty payments to Royalty Pharma.” SEC filing

“In 2023, we entered into a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with Lp(a)-driven CVD.” SEC filing

“In 2017, we initiated a collaboration with Novartis to develop and commercialize pelacarsen.” SEC filing

“Novartis is also entitled to low-to-mid single digit percentage royalties from commercial sales of the product.” SEC filing

“The Company recorded costs associated with the license agreement from Novartis of $ 10.0 million as research and development expenses for the year ended December 31, 2020.” SEC filing

“...nd develop TIL cell therapies in new indications in clinical trials, we currently work and collaborate with government and academic research institutions, medical institutions, and corporate partners such as the NCI, Moffitt, Memorial Sloan Kettering Cancer Center, or MSKCC, Cellectis, and Novartis.” SEC filing

“In August 2019, Pharming entered into a development collaboration and license agreement with Novartis to develop and commercialize leniolisib, the P13Kδ inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome, or APDS.” SEC filing

“Pursuant to our agreement with Novartis relating to Joenja®, we have agreed to manufacture both the drug substance as well as the drug product via our own Contract Manufacturing Organizations, or CMOs.” SEC filing

“We recognize royalty revenue from net sales of Zolgensma and Itvisma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require us to estimate royalty revenue for periods of net sales which have not yet been reported to us.” SEC filing

“One customer (Novartis Gene Therapies) accounted for approximately 98% of our total revenues for the year ended December 31, 2024.” SEC filing

“We have no obligation to repay any amounts to HCR if total future Zolgensma and Itvisma royalty payments from Novartis are not sufficient to repay these amounts.” SEC filing

“Zolgensma and Itvisma are licensed products under our license agreement with Novartis Gene Therapies for the development and commercialization of treatments for SMA using the NAV Technology Platform.” SEC filing

“...ation payable to the Company under specified license agreements (collectively, the Royalty Interest), including (i) the Novartis License for Zolgensma and Itvisma, (ii) the collaboration and license agreement with Nippon Shinyaku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agr...” SEC filing

“Under the terms of the research collaboration and license agreement, Novartis paid us an initial upfront fee of $150.0 million in January 2025 and we are eligible to receive up to $2.272 billion in total milestone payments across the initial programs.” SEC filing

“Under our collaboration with Novartis, for example, we are prohibited from researching, developing, manufacturing, modifying, improving or commercializing any small molecule directed against collaboration targets ourselves or with a third party during a specified period and subject to specified exce...” SEC filing

“Novartis: In June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.” SEC filing

“Novartis: In June 2016, we entered into a Collaboration and License Agreement (the "Novartis Agreement") with Novartis to develop and commercialize bispecific and other Fc-engineered antibody product candidates using our proprietary XmAb® technologies.” SEC filing

“Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"), Novo Nordisk, Eli Lilly, and Chinook (now a Novartis company).” SEC filing

“Autologous T cell therapies directed at CD19 have been commercialized by Novartis, Kite/Gilead and Bristol-Myers Squibb Company (BMS) and are witnessing increased adoption in the marketplace.” SEC filing

“Pursuant to the Novartis Asset Agreement, we sold to Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR.” SEC filing

“Although we may receive potential future payments under our collaborations, including with Pfizer and Genentech, and our out-license to Novartis, we do not currently have any committed external source of funds.” SEC filing

“Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred.” SEC filing

“Pfizer, Genentech and Novartis have the first right to enforce or defend certain intellectual property rights under the applicable collaboration arrangement or license agreement with respect to particular licensed programs, and although we may have the right to assume the enforcement and defense of...” SEC filing

“On a target-by-target basis, if Novartis elected to progress development candidates directed to such target into further development, Novartis would have been responsible for all future development, manufacturing and commercialization activities and be required to use commercially reasonable efforts...” SEC filing

“On March 27, 2023, the Company and Novartis entered into a collaboration and license agreement (the "Novartis Collaboration Agreement"), pursuant to which the parties agreed to perform research and discovery activities during a research term of up to a specified number of years per target program to...” SEC filing

“..., compared to the year ended December 31, 2024, primarily due to increases of $38.8 million from our collaboration with Novartis primarily due to the recognition of all remaining revenue upon a notice of termination from Novartis in November 2025, effective in February 2026, as well as $5.5 million...” SEC filing

“...strative expenses in the consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $ 10.6 million and the final remeasurement of the CVR liability related to NZV930 of $ 3.8 million to its fair value of zero .” SEC filing

“WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer and Roche, generating several hundred million dollars in sales annually.” SEC filing

“Revenue from Novartis Pharma AG ("Novartis") and Imugene (defined below) accounted for 77 % and 23 % of revenue during the year ended December 31, 2025, respectively.” SEC filing

“Collaboration and License Agreement with Novartis” SEC filing

“The change in cash used in operating assets and liabilities was primarily driven by the net changes of deferred revenue as a result of the conclusion of Novartis collaboration in the year ended December 31, 2025 and the conclusion of the Prevail collaboration in the year ended December 31, 2024.” SEC filing

“Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron.” SEC filing

“We control the prosecution and maintenance of the patents exclusively licensed to us, with Novartis retaining step-in rights if we do not continue such prosecution and maintenance.” SEC filing

“Under the license agreement, Novartis granted to us a worldwide, exclusive, sublicensable license to research, develop, manufacture, and commercialize certain defined compounds and products, including IDE196 and certain other PKC inhibitors, as well as companion diagnostic products, collectively ref...” SEC filing

“Subsequent to 30 June 2026, Novartis gave notice terminating the out-license agreement relating to ieramilimab, effective 9 August 2026.” SEC filing

“In August 2026, the exclusive license and collaboration agreement was terminated on notice from Novartis and the asset is in the process of being transferred back to Immutep.” SEC filing

“Under the terms of the license agreement, Novartis is entitled to receive up to $8.0 million in development milestones and up to $27.0 million in commercial milestones.” SEC filing

“See "Item 4.B - Business Overview-License and Collaboration Agreements" for information regarding the Novartis Option Agreement, the Ensovibep License Agreement and the Novartis Radioligand Agreement with Novartis.” SEC filing

“Revenues in prior years were exclusively driven by the Novartis collaboration agreement for radioligand therapies.” SEC filing

“Business-Material Agreements-Licensing Agreement with AstraZeneca," under various agreements with Novartis and AstraZeneca, Mereo has agreed to make milestone payments and pay royalties.” SEC filing

“We have strong relationships with these companies, as evidenced by our agreements with Novartis AG ("Novartis") and AstraZeneca AB ("AstraZeneca"), as well as our partnership with Ultragenyx, and a track record of structuring transactions that enable us to leverage our core capabilities while creati...” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“In addition, as of December 31, 2025, we exclusively licensed from Novartis under the Novartis Agreement, in the licensed field as defined in the Novartis Agreement, one patent family directed on a biomarker for patient selection, that consists of one issued U.S. patent and one issued Japanese paten...” SEC filing

“License Agreement, dated December 22, 2014, by and between Novartis Pharma AG and the registrant (relating to AQW051) (filed as Exhibit 10.62 to the registrant's annual report on Form 10-K (File No. 001-34186) on March 13, 2015 and incorporated herein by reference).” SEC filing

“The promises at inception do not include the underlying goods or services that would be delivered upon exercise of the option but rather represent the value to the customer of having the right to exercise the Novartis License Option at the specified exercise fee.” SEC filing

“Following the termination of the two programs, the licenses we granted to Novartis regarding the applicable Initial Novartis Target and the Novartis Direct License Target expired, and all intellectual property rights that we licensed to Novartis with respect to such programs reverted to us in accord...” SEC filing

“Under the terms of the 2022 Novartis Option and License Agreement, Novartis paid us an upfront payment of $54.0 million.” SEC filing

“In addition to the Neurocrine collaborations, we have partnered with Novartis on TRACER Capsid-based gene therapies for spinal muscular atrophy and Huntington's disease.” SEC filing

“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing

“In May 2019, we entered into a Platform Technology Transfer and License Agreement (the "Novartis CodeEvolver” SEC filing

“...tion, some of our agreements, including the agreements with GlaxoSmithKline plc ("GSK"), Merck Sharp & Dohme ("Merck"), Novartis Pharma AG ("Novartis"), Nestlé Health Science ("Nestlé"), Aldevro n LLC, Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for milestone...” SEC filing

“The Company also has the potential to receive quantity-dependent, usage payments for each API that is manufactured by Novartis using one or more enzymes that have been developed or are in development using the CodeEvolver technology platform during the period beginning on the conclusion of the Techn...” SEC filing

“In December 2022, the Company entered into an exclusive license agreement (as amended, the Novartis Agreement) with Novartis Pharma AG (Novartis) under which the Company was granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or con...” SEC filing

“received FDA approval for Mekinist (trametinib), that was subsequently sold to Novartis AG; Pfizer Inc., which received FDA approval for” SEC filing

“Under the Novartis License Agreement, Novartis has agreed to pay up to $1.01 billion in milestone payments upon achievement of specified clinical, regulatory and commercial milestones, as well as tiered royalties on net sales.” SEC filing

“Even if we succeed in securing collaborators for the development and commercialization of our product candidates, such as the Janssen Agreement or the Novartis License” SEC filing

“commercial supply agreements for BCMA CAR-T product with Novartis Pharmaceuticals Corporation (the "Novartis Supply Agreements"), pursuant to which Novartis agreed to manufacture cilta-cel for our clinical and commercial use to supplement our existing manufacturing capabilities.” SEC filing

“Collaboration and License Agreement by and between the Registrant and Novartis Institutes for Biomedical Research, dated as of March 27, 2020 (incorporated by reference to Exhibit 10.8 to the Registrant's Registration Statement on S-1 filed with the Securities and Exchange Commission on April 23, 20...” SEC filing

“In January 2021, the Company entered into a collaboration and license agreement with Novartis, granting Novartis rights to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan (the "Novartis Territory").” SEC filing

“...ty revenue from IMDELLTRA ® sales outside of China under the Amgen collaboration agreement, revenue generated under the Novartis broad markets agreement, and research and development services revenue and right to access intellectual property revenue from its former collaboration agreements with Nova...” SEC filing

“License Agreement with Novartis for Dovitinib” SEC filing

“In 2021, we entered into a clinical collaboration with Novartis Pharma AG, or Novartis, to evaluate the combination of tipifarnib and alpelisib, a PI3K alpha inhibitor, in patients with HNSCC whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification.” SEC filing

“The Novartis Amendment, among other things, expanded the Company's clinical collaboration with Novartis, increasing the size of the ongoing Phase 1/2 study testing palazestrant in combination with ribociclib to approximately 60 patients.” SEC filing

“Clinical Collaboration and Supply Agreement with Novartis” SEC filing

“...ompanies developing inhibitors against PRC2 via EZH2 inhibition that are currently in clinical trials, including Ipsen, Novartis, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical, Treeline Biosciences in collaboration with Jiangsu HengRui Medicine Co., Evopoint Biosciences and Hanmi Pharmaceuti...” SEC filing

“We have incurred significant net losses since our inception and have financed our operations principally through equity and debt financing and our prior collaboration with Novartis Institute for Biomedical Research, Inc. ("Novartis").” SEC filing

“We are dependent on patents, know-how and proprietary technology licensed or sublicensed to us from Ares, Novartis, and Stanford.” SEC filing

“As of December 31, 2025, our patent portfolio licensed from Novartis and covering MAU868 includes three issued U.S. patents with claims covering the composition of matter of MAU868, and methods of neutralizing BKV or JC virus as well as methods of treating or reducing the likelihood of BKV or JC vir...” SEC filing

“...ia Therapeutics evaluating a sigma-1 receptor agonist, (v) PTC Therapeutics evaluating a splicing modifier (licensed to Novartis), (vi) Sarepta Therapeutics evaluating an siRNA, (vii) Skyhawk Therapeutics evaluating a splicing modifier, (viii) uniQure evaluating an AAV-delivered miRNA, (ix) Vaccinex...” SEC filing

“• Parkinson's disease - ARO-SNCA (out-licensed to Novartis)” SEC filing

“On August 29, 2025, the Company entered into an Exclusive License and Collaboration Agreement (the "Novartis Collaboration Agreement") with Novartis Pharma AG ("Novartis") for the co-development and commercialization of multiple preclinical programs in rare, genetic diseases.” SEC filing

“...under the brand names Eylea® and EyleaHD®; brolucizumab, a single chain antibody fragment approved in 2019 and sold by Novartis AG under the brand name Beovu®; and faricimab, a bispecific antibody targeting both VEGF and angiopoietin-2, approved in 2022 and sold by Roche under the brand name Vabysm...” SEC filing

“Cost of revenues in each period consisted of the write-off of the remaining carrying value of the definite-lived intangible asset associated with royalty rights sold to Simcere pursuant to the Simcere Agreement in 2025 and to Novartis pursuant to the Settlement Agreement in 2024.” SEC filing

“Other than already approved programs (i.e. Simcere's Enzeshu®, Novartis' Beovu®) there is no guarantee that any of the other product candidates discovered using our APXiMAB Platform, whether developed by us or our licensees, will receive regulatory approval.” SEC filing

“...mpanies have already received regulatory approvals for their anti-PD-1/PD-L1 antibodies, including AstraZeneca, BeiGene/Novartis, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-P...” SEC filing

“Innovative Therapies AG (together, "Novartis"), pursuant to which the Company agreed to purchase from Novartis the exclusive” SEC filing

“| License Agreement by and between NewcelX Ltd. and Novartis Pharma AG, dated March 10, 2021 (filed as Exhibit 4.6 to Annual Report on Form 20-F filed on May 14, 2021). |” SEC filing

“| | ● | | the progress and results of activities for our votoplam program, including our right to receive any development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; and |” SEC filing

“Business - Our Collaborations, License Agreements and Funding Arrangements - Novartis Pharmaceuticals Corporation."” SEC filing

“While Novartis has taken over responsibility for further development of the votoplam program, we continue to collaborate with Novartis on next steps .” SEC filing

“...t cash provided by operating activities for the year ended December 31, 2025, was primarily related to the upfront payment of $1.0 billion in cash received upon the closing of the Novartis Agreement in January 2025, partially offset by spend supporting clinical development and commercial activities.” SEC filing

“Novartis, Zuelling and Alcon - accounted for approximately 53.7% of the company's total revenue for the year ended December” SEC filing

“global pharmaceutical companies such as Novartis and Alcon, as well as having licensing partnerships with EG BioMed for pancreatic and” SEC filing

“Neuropharmacology Biomarkers: Collaborative research with Novartis evaluated the pharmacodynamic effects of MIJ821 (onfasprodil) using our EEG analytics as an objective CNS biomarker in a Phase I first-in-human study, published in Clinical and Translational Science (2023).” SEC filing

“The goods and services that the Company is obligated to deliver and perform under the 2025 Novartis Agreement will be accounted for under ASC 606 as they represent a transaction with a customer.” SEC filing

“Our patent portfolio related to our VAV1 program has been exclusively licensed to Novartis.” SEC filing

“In October 2024, we entered into a license agreement with Novartis, or the 2024 Novartis Agreement.” SEC filing

“We expect that our collaborator, Novartis, will initiate multiple Phase 2 studies of MRT-6160 in immune-mediated diseases in 2026.” SEC filing

“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.” SEC filing